Petru Ifteni

Prof. Dr. Petru Ifteni


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

19 March 2018 in Molecules
Verified
Journal Article
Open access
PDF file
Marius MogaMarius Moga
Marius Moga
ODOana Gabriela Dimienescu
Oana Gabriela Dimienescu
CACristian Andrei Arvatescu
Cristian Andrei Arvatescu
PIPetru Ifteni
Petru Ifteni
LPLiana Pleş
Liana Pleş
Cancer represents the disease of the millennium, a major problem in public health. The proliferation of tumor cells, angiogenesis, and the relationship between the cancer cells and the components of the extracellular matrix are important in the events of carcinogenesis, and these pathways are being used as targets for new anticancer treatments. Various venoms and their toxins have shown possible anticancer effects on human cancer cell lines, providing new perspectives in drug development. In this review, we observed the effects of natural toxins from bee and snake venom and the mechanisms through which they can inhibit the growth and proliferation of cancer cells. We also researched how several types of natural molecules from venom can sensitize ovarian cancer cells to conventional chemotherapy, with many toxins being helpful for developing new anticancer drugs. This approach could improve the efficiency of standard therapies and could allow the administration of decreased doses of chemotherapy. Natural toxins from bee and snake venom could become potential candidates for the future treatment of different types of cancer. It is important to continue these studies concerning therapeutic drugs from natural resource and, more importantly, to investigate their mechanism of action on cancer cells.

1 June 2020 in Schizophrenia Research
Verified
Journal Article
Closed access
PIPetru Ifteni
Petru Ifteni
LDLorena Dima
Lorena Dima
ATAndreea Aliana Teodorescu
Andreea Aliana Teodorescu

28 December 2022 in Journal of Affective Disorders
Verified
Journal Article
Closed access
MSMarco Solm
Marco Solm
TTTrevor Thompson
Trevor Thompson
AEAndrés Estradé
Andrés Estradé
Agorastos AgorastosAgorastos Agorastos
Agorastos Agorastos
Joaquim RaduàJoaquim Raduà
Joaquim Raduà
CCChristoph Correll
Christoph Correll

12 September 2020 in Psychiatric Quarterly
Verified
Journal Article
Closed access
PDF file
ATAndreea Teodorescu
Andreea Teodorescu
PIPetru Ifteni
Petru Ifteni
AMAna Aliana Miron
Ana Aliana Miron
PPPaula Simina Petric
Paula Simina Petric
LDLorena Dima
Lorena Dima

20 March 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
LDLiliana Duca
Liliana Duca
NRNadinne Roman
Nadinne Roman
ATAndreea Aliana Teodorescu
Andreea Aliana Teodorescu
PIPetru Ifteni
Petru Ifteni
As a complication of systemic lupus erythematosus (SLE), the neuropsychiatric form may manifest with neurological and psychiatric symptoms. Diagnosing neuropsychiatric SLE can be challenging due to the heterogeneity of this disease manifestation and the possibilities of investigation. This research aims to identify the possible associations between inflammation and thrombotic biomarkers alongside anxiety and/or depression manifestations in SLE patients. A group of 65 outpatients were investigated regarding the levels of depression, anxiety, disability, quality of life and other specific serum biomarkers linked with inflammation or coagulopathies. The results showed severe depression in eight participants, moderate depression in 22 (33.85%), and 26 (40%) subjects with mild depression. Anxiety was more prevalent within 64 participants (98.46%), while a degree of disability was reported by 52 participants (80%). Quality of life evaluated by EQ5D revealed a medium value of 1.57, and EQ5D VAS health medium value was 57.95 and was correlated with anxiety. A strong positive correlation between depression, anxiety and antibodies associated with anti-cardiolipin and anti beta2 glycoprotein I antibodies, lupus anticoagulant, ICAM-1, low C4 a and anti-ribosomal P antibodies were identified. These data results suggest that autoimmune/inflammatory and ischemic/thrombotic pathways could contribute to depression and anxiety as neuropsychiatric SLE manifestations.